Advantage Alpha Capital Partners LP Trims Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Advantage Alpha Capital Partners LP reduced its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 71.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 101,558 shares of the company's stock after selling 256,896 shares during the period. Advantage Alpha Capital Partners LP owned about 0.08% of Organogenesis worth $290,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ORGO. Price T Rowe Associates Inc. MD boosted its stake in shares of Organogenesis by 11.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company's stock valued at $145,000 after purchasing an additional 5,359 shares in the last quarter. Caxton Associates LP purchased a new stake in shares of Organogenesis during the 1st quarter worth $88,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Organogenesis by 349.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 186,236 shares of the company's stock worth $529,000 after purchasing an additional 144,771 shares during the last quarter. CWM LLC boosted its position in Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company's stock valued at $72,000 after purchasing an additional 19,242 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company's stock valued at $11,136,000 after purchasing an additional 3,005,450 shares during the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Stock Down 1.5 %

Organogenesis stock traded down $0.06 during trading hours on Wednesday, reaching $3.90. The stock had a trading volume of 413,574 shares, compared to its average volume of 826,981. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70. The company has a market cap of $517.05 million, a price-to-earnings ratio of -65.00 and a beta of 1.60. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The business's 50 day moving average price is $3.23 and its 200-day moving average price is $2.91.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the previous year, the firm earned $0.02 earnings per share. Sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.